Related Experiment Video

Updated: Jun 11, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling

Jamie B Spangler1, Jason R Neil, Sivan Abramovitch

  • 1Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Proceedings of the National Academy of Sciences of the United States of America
|July 10, 2010
PubMed

Insights

Combinations of two noncompetitive monoclonal antibodies targeting epidermal growth factor receptor (EGFR) significantly reduce receptor levels by inhibiting recycling. This EGFR antibody therapy approach offers a novel strategy for cancer treatment by reducing cell migration and proliferation.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) is frequently dysregulated in epithelial cancers, making it a key target for anticancer therapies.
  • Monoclonal antibodies (mAbs) targeting EGFR are established anticancer drugs, with ongoing development of new antibody-based therapeutics.

Purpose of the Study:

  • To elucidate the mechanism and impact of noncompetitive mAb combinations on EGFR down-regulation.
  • To investigate the effect of mAb-induced EGFR down-regulation on cancer cell behavior.

Main Methods:

  • Utilized combinations of two noncompetitive mAbs targeting EGFR domain 3.
  • Quantified surface EGFR levels and receptor down-regulation kinetics in normal and transformed human cell lines.
  • Investigated the mechanism of down-regulation through recycling inhibition assays.
  • Assessed EGFR activation and downstream signaling pathways.
  • Evaluated the synergistic effects on cell migration and proliferation in cells with autocrine ligand secretion.

Main Results:

  • Potent mAb combinations reduced surface EGFR levels by up to 80% with a half-time of 0.5-5 hours, inversely proportional to receptor density.
  • The primary mechanism of EGFR reduction was identified as recycling inhibition.
  • Unlike ligand-induced down-regulation, mAb-induced EGFR reduction did not activate EGFR or its downstream effectors.
  • Synergistic reduction in migration and proliferation was observed in cells secreting autocrine ligand.

Conclusions:

  • Noncompetitive mAb combinations provide a potent and specific method for EGFR down-regulation via recycling inhibition.
  • This EGFR-targeted antibody approach offers a non-agonistic strategy that reduces cancer cell migration and proliferation.
  • These findings support the rational design of novel EGFR-targeted antibody therapeutics for cancer treatment.

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Recycling Endosomes and Transcytosis00:58

Recycling Endosomes and Transcytosis

The recycling endosome, also known as the endosomal recycling compartment (ERC), is a part of the slow-recycling process of the endocytic pathway. Molecules internalized through receptor-mediated endocytosis are either degraded in the lysosomes or are recycled to the plasma membrane through the fast- or slow-recycling route.
The recycling endosome is not a single organelle but an extensively tubulated network of recycling pathways. It functions in storing molecules or transporting them across...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...